Hyperlipoproteinemia type i
Calderín, F.M.; Perianes, J.; Nuño, J.; De Oya, M.
Revista Clinica Espanola 147(1): 81-84
1977
ISSN/ISBN: 0014-2565 PMID: 618357 Document Number: 116784
Document emailed within 1 workday
Related Documents
Arntz, H.R.; Klemens, U.H.; Vollmar, L.J.; Lang, P.D. 1978: Comparison of clofibrate and bezafibrate in type IIa and type IIb hyperlipoproteinemia Medizinische Klinik 73(49): 1731-1737Bolzano, K.; Krempler, F.; Schellenberg, B.; Schlierf, G. 1979: A comparison of bezafibrate and clofibrate in type Ii B and type IV hyperlipoproteinemia Acta Medica Austriaca 6(3): 90-94
Bustos, P.; Fernández, E.; Radrigán, E. 1987: Hyperlipoproteinemia type i Revista Chilena de Pediatria 58(6): 481-484
Heckers, H.; Oehler, G. 1975: Type-V-hyperlipoproteinemia Die Medizinische Welt 26(39): 1766-1774
Morrone, G.; Franco, G.; Di Muccio, G.; Cappello, A. 1978: A case of type IV hyperlipoproteinemia La Pediatria 86(4): 667-677
Matsuura, F. 2007: Familial hyperlipoproteinemia, type IV Nihon Rinsho. Japanese Journal of Clinical Medicine 65(Suppl 7): 326-328
Di Gruttola, G.; Ferrara, M. 1977: Familial congenital type IIB hyperlipoproteinemia La Pediatria 85(3): 435-442
Schoenborn, W.; Fuhrmann, W.; Huth, K. 1973: Hyperlipoproteinemia type 3 in kidney diseases Verhandlungen der Deutschen Gesellschaft für Innere Medizin 79: 1280-1283
Schwartzkopff, W.; Schilling, A.; Calder, D. 1980: Therapy of hyperlipoproteinemia type IIa, IIb and IV with Etofibrate retard Die Medizinische Welt 31(14): 515-520
Hagve, T.A.; Furuset, T.; Christophersen, B.; Ose, L. 1993: Apolipoprotein e phenotyping--useful in the study of hyperlipoproteinemia type IIi Tidsskrift for den Norske Laegeforening: Tidsskrift for Praktisk Medicin Ny Raekke 113(7): 853-856
Andersen, G.E.; Friis-Hansen, B. 1976: Neonatal diagnosis of familial type Ii hyperlipoproteinemia Pediatrics 57(2): 214-220
Masket, B.H.; Levy, R.I.; Fredrickson, D.S. 1973: The use of polyacrylamide gel electrophoresis in differentiating type 3 hyperlipoproteinemia Journal of Laboratory and Clinical Medicine 81(5): 794-802
Mertz, D.P.; Suermann, I.; Göhmann, E. 1978: Clofibrate in type IIa hyperlipoproteinemia. Reduction of apolipoprotein B Münchener Medizinische Wochenschrift 120(34): 1097-1099
Traurig, J.; Sobra, J.; Kvasilová, M.; Wildtová, Z. 1978: Familial hyperlipoproteinemia type IIA with homozygotic manifestations in a heterozygote Vnitrni Lekarstvi 24(7): 684-690
Denmacker, P.N.; Vos-Janssen, H.E.; Stuyt, P.M.; Schade, R.W.; Jansen, A.P.; van 't Laar, A. 1978: Application and comparison of different criteria used for the diagnosis of type IIi hyperlipoproteinemia Clinical Chemistry 24(9): 1445-1451
Hsia, S.H.; Connelly, P.W.; Hegele, R.A. 1995: Restriction isotyping of apolipoprotein E R145C in type III hyperlipoproteinemia Journal of Investigative Medicine: the Official Publication of the American Federation for Clinical Research 43(2): 187-194
Arranz Peña, M.L.; Alonso de la Peña, M.C. 1985: Hyperlipoproteinemia type I. Study of a familial deficiency of lipoprotein-lipase Revista Clinica Espanola 176(2): 98-100
Knüchel, F. 1974: Effect of a new lipid-reducing preparation (Etofibrat) on hyperlipoproteinemia type II. 2 Die Medizinische Welt 25(44): 1810-1812
Mikheev, G.N.; Smirnov, A.V.; Sazonets, G.I.; Kozhevnikov, A.D. 1986: Use of entero-and hemosorption in a patients with diabetic xanthomatosis and hyperlipoproteinemia type V Klinicheskaia Meditsina 64(11): 132-134
Shinomiya, M.; Ishikawa, Y.; Shirai, K.; Saito, Y.; Yoshida, S. 1987: Effect of pirozadil on lipids, lipoproteins and apolipoproteins in Japanese with type IIa hyperlipoproteinemia Arzneimittel-Forschung 37(9): 1069-1071